Voranigo (vorasidenib) — Highmark
Grade 2 astrocytoma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection
Initial criteria
- age ≥ 12 years
- Diagnosis of Grade 2 astrocytoma or Grade 2 oligodendroglioma with a susceptible IDH1 or IDH2 mutation as detected by an FDA-approved test
- Request is following surgery including biopsy, sub-total resection, or gross total resection
Reauthorization criteria
- Prescriber attests that the member is tolerating therapy
- Member has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months